Hepatology International最新文献

{"title":"Paradoxical association between steatotic liver disease and favorable hepatic outcomes in HCV patients with SVRs.","authors":"Ming-Ling Chang, Jur-Shan Cheng, Jennifer Tai, Wei-Ting Chen, Sien-Sing Yang, Cheng-Hsun Chiu, Rong-Nan Chien, Chia-Lin Hsu, Shang-Jung Wu, Cathy Sj Fann","doi":"10.1007/s12072-025-10906-3","DOIUrl":"https://doi.org/10.1007/s12072-025-10906-3","url":null,"abstract":"<p><strong>Background: </strong>The effects of genetic predispositions and steatotic liver disease (SLD) on the outcomes of chronic hepatitis C (CHC) patients with sustained virological responses (SVRs) remain unknown.</p><p><strong>Methods: </strong>A 15-year prospective study of CHC patients with SVRs was conducted.</p><p><strong>Results: </strong>Among 965 SVR patients, the baseline and 24-week post-HCV therapy SLD rates were 64% and 54%, respectively; the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M-rs738409 G allele was negatively correlated with the methylenetetrahydrofolate reductase (MTHFR) C677T Ala222Val-rs1801133 T allele (Pearson's correlation: -0.078, p = 0.025). At baseline, body mass index (BMI) (OR: 1.18; 95% CI: 1.12-1.25), cirrhosis (0.34; 0.20-0.56) and the PNPLA3 G allele (1.28; 1.03-1.60) were associated with SLD. At 24 weeks posttherapy, BMI (1.16; 1.09-1.24), the fibrosis-4 index (0.86; 0.75-0.99), cirrhosis (0.23; 0.14-0.40), HOMA-IR (1.16; 1.04-1.30), the ALT level (1.01; 1.00-1.03) and the MTHFR T allele (0.66; 0.48-0.91) were associated with 24-week SLD in SVR patients. Longitudinally, compared with sex- and age-matched patients without 24-week SLD, patients with 24-week SLD had higher BMIs and ALT levels, poorer metabolic profiles, and greater cumulative incidences of cardiovascular events (70.9% vs. 63.7%, p = 0.026) but lower fibrosis-4 indices and cumulative incidences of cirrhosis (12.7% vs. 31.5%, p < 0.001) and HCC (4.6% vs. 12.1%, p < 0.001). A 24-week SLD was negatively associated with the cumulative incidences of cirrhosis (HR: 0.548; 95% CI HR: 0.281 ~ 0.894) and HCC (0.637; 0.32 ~ 0.99).</p><p><strong>Conclusions: </strong>Poorer metabolic profiles and greater cardiovascular but lower hepatic event cumulative incidences were noted in patients with than in those without 24-week SLD. The paradoxical association between SLD and hepatic events might stem from the negative correlation between the PNPLA3 G allele and the MTHFR T allele, which are HCV-specific SLD factors.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Letter to the Editor on \"Acute kidney injury stage 1a increases mortality of patients with cirrhosis-a prospective multicenter cohort study\".","authors":"Angelo Z Mattos, Muriel Manica, Angelo A Mattos","doi":"10.1007/s12072-025-10904-5","DOIUrl":"https://doi.org/10.1007/s12072-025-10904-5","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Cao et al.: Expanding machine learning-based non-invasive non-selective beta blockers monitoring.","authors":"Mauro Giuffrè","doi":"10.1007/s12072-025-10905-4","DOIUrl":"https://doi.org/10.1007/s12072-025-10905-4","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor \"Methodological considerations for recombinant human serum albumin clinical translation\".","authors":"Xinrui Wang, Junqi Niu","doi":"10.1007/s12072-025-10901-8","DOIUrl":"https://doi.org/10.1007/s12072-025-10901-8","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological considerations for recombinant human serum albumin clinical translation.","authors":"Linye Pan, Bing Ruan","doi":"10.1007/s12072-025-10896-2","DOIUrl":"10.1007/s12072-025-10896-2","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: comment on \"Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma\".","authors":"Yukihiro Watanabe, Masayasu Aikawa, Yoshiki Murase, Kenichiro Takase, Yuichiro Watanabe, Hiroaki Ono, Katsuya Okada, Kojun Okamoto, Isamu Koyama","doi":"10.1007/s12072-025-10900-9","DOIUrl":"https://doi.org/10.1007/s12072-025-10900-9","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on: stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma.","authors":"Ziheng Peng, Qixin Liu","doi":"10.1007/s12072-025-10899-z","DOIUrl":"10.1007/s12072-025-10899-z","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.","authors":"Masatsugu Ohara, Goki Suda, Risako Kohya, Yutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, Joji Tani, Shinya Maekawa, Nobuyuki Enomoto, Makoto Chuma, Manabu Morimoto, Shun Kaneko, Mina Nakagawa, Yasuhiro Asahina, Atsumasa Komori, Yuki Kugiyama, Masaru Baba, Akihisa Nakamura, Jun Ito, Ren Yamada, Shunichi Hosoda, Yoshiya Yamamoto, Sonoe Yoshida, Takuya Sho, Takashi Sasaki, Tomoka Yoda, Akimitsu Meno, Naohiro Yasuura, Qingjie Fu, Zijian Yang, Osamu Maehara, Shunsuke Ohnishi, Yoshimasa Tokuchi, Takashi Kitagataya, Naoki Kawagishi, Masato Nakai, Koji Ogawa, Naoya Sakamoto","doi":"10.1007/s12072-025-10875-7","DOIUrl":"https://doi.org/10.1007/s12072-025-10875-7","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality. Although the atezolizumab/bevacizumab regimen demonstrated impressive efficacy in the IMbrave150 clinical trial, long-term outcomes, particularly 3-year overall survival (OS), remain unestablished because of limited follow-up. Long-term outcomes have been reported for the tremelimumab/durvalumab combination, highlighting the need for comparable data on atezolizumab/bevacizumab. We aimed to elucidate the 3-year OS in patients with unresectable HCC (uHCC) treated with atezolizumab plus bevacizumab.</p><p><strong>Methods: </strong>This retrospective multicenter study included patients with uHCC who received atezolizumab/bevacizumab. Among the 506 patients treated at the participating institutions, only those who initiated therapy between October 2020 and January 2022 were included. Comprehensive clinical, laboratory, and imaging data were collected, and the patients were followed up until March 2025.</p><p><strong>Results: </strong>A total of 257 patients were analyzed, with a median follow-up of 48.23 months (range, 36.23-53.60 months). The 2- and 3-year OS rates were 39.2% and 25.3%, respectively. Among patients meeting the IMbrave150 criteria, the 3-year OS rate was 31.6%. Multivariate regression analysis identified baseline alpha-fetoprotein level > 116 ng/mL (odds ratio [OR] 0.41; 95% confidence interval [CI] 0.20-0.84; p = 0.015) and modified albumin-bilirubin grade 1-2a (OR 2.50; 95% CI 1.18-5.32; p = 0.017) as significant factors associated with 3-year OS.</p><p><strong>Conclusions: </strong>In a real-world setting, the 3-year OS for uHCC patients treated with atezolizumab/bevacizumab was 25.3%, rising to 31.6% among those meeting the IMbrave150 criteria. Survival outcomes underscore the clinical value of atezolizumab/bevacizumab in improving long-term prognosis and guiding first-line treatment decisions for patients with unresectable HCC.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study.","authors":"Ningning Zhang, Kaipeng Liu, Yuexi Yu, Kai Yuan, Haipeng Yu, Jean Charles Nault, Claudia Campani, Lorraine Blaise, Sara Mouri, Eleonore Spitzer, Yawei Du, Shuwen Zhang, Wenwen Zhu, Hao Yu, Tian Liu, Xuanchen Liu, Ming Luo, Huiru Liu, Yiyan Zhang, Yiming Huo, Feng Duan, Manon Allaire, Wei Lu, Jihui Hao","doi":"10.1007/s12072-025-10895-3","DOIUrl":"https://doi.org/10.1007/s12072-025-10895-3","url":null,"abstract":"<p><strong>Background and aims: </strong>Transarterial chemoembolization (TACE) combined with immunotherapy and targeted therapy provides a promising therapy for unresectable hepatocellular carcinoma (HCC). This study aimed to compare the efficacy and safety of TACE combined with atezolizumab and bevacizumab (TACE-Ate-Bev) or atezolizumab and bevacizumab alone (Ate-Bev) as first-line treatment for unresectable HCC.</p><p><strong>Methods: </strong>This multicenter cohort study recruited patients with unresectable HCC who received TACE-Ate-Bev or Ate-Bev as first-line treatment between July 1, 2020 and December 31, 2023. Inverse probability of treatment weighting (IPTW) was employed to minimize bias. Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were observed.</p><p><strong>Results: </strong>311 patients were included in this analysis, with 152 in the TACE-Ate-Bev group and 159 in the Ate-Bev group. The TACE-Ate-Bev group demonstrated significantly improved OS (26.8 [95% CI 23.1-NR] vs. 14.9 [95% CI 11.4-19.9] months, p < 0.0001) and PFS (16.0 [95% CI 12.8-17.8] vs. 6.5 [95% CI 5.4-7.6] months, p < 0.0001) compared to the Ate-Bev group, both in BCLC stage B (mOS: NR vs. 15.6 months, p < 0.0001; mPFS: 16.9 vs. 6.7 months, p < 0.0001) and BCLC stage C (mOS: 25.2 vs. 14.3 months, p = 0.00018; mPFS: 12.8 vs. 6.5 months, p < 0.0001) disease. After IPTW adjustment, the TACE-Ate-Bev group also demonstrated significantly improved OS and PFS compared to the Ate-Bev group, both in BCLC stage B and BCLC stage C disease. Grade 3-4 AEs were observed in 36 patients (24.3%) in the TACE-Ate-Bev group and 34 (21.4%) in the Ate-Bev group. There was no statistically significant difference in the proportion of gastrointestinal bleeding between the TACE-Ate-Bev and Ate-Bev groups (9.9 vs. 10.1%, p = 0.954).</p><p><strong>Conclusion: </strong>TACE-Ate-Bev significantly improves OS and PFS with acceptable toxicity compared with Ate-Bev as first-line therapy for unresectable HCC.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma\".","authors":"Zhiyao Shi, Kai Feng, Yu Gao, Xixing Wang","doi":"10.1007/s12072-025-10897-1","DOIUrl":"https://doi.org/10.1007/s12072-025-10897-1","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}